Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Inhaled RJ026 in ILD and Healthy Volunteers
NCT06992661Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RJ026 in interstitial lung disease (ILD) (8 arms), sponsored by Ruijin Hospital. Primary endpoint: Area Under the Curve from time 0 to 24 hours of blood samples in ILD patients. Started May 2025; status: recruiting.
02
Drugs
RJ026
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT06992661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06992661.